<DOC>
	<DOCNO>NCT00077155</DOCNO>
	<brief_summary>This phase I trial study side effect best dose EMD 121974 treat patient solid tumor lymphoma . Cilengitide ( EMD 121974 ) may stop growth cancer cell stop blood flow cancer</brief_summary>
	<brief_title>Cilengitide ( EMD 121974 ) Treating Patients With Advanced Solid Tumors Lymphoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity , maximum feasible dose , recommend phase II dose cilengitide ( EMD 121974 ) patient advance solid tumor lymphoma . II . Determine safety tolerability drug patient . SECONDARY OBJECTIVES : I . Determine pharmacokinetics drug patient . II . Determine antineoplastic activity drug patient . OUTLINE : This dose-escalation study . Patients receive cilengitide ( EMD 121974 ) IV continuously week 1-4 . Courses repeat every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos EMD 121974 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<criteria>Histologically confirm solid tumor lymphoma Refractory standard therapy standard therapy exist Measurable evaluable disease No active brain metastasis Previously treat brain metastasis allow provided patient currently receive corticosteroid Primary brain neoplasm allow , regardless corticosteroid use Performance status Karnofsky 70100 % WBC ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 No lifethreatening bleed diathesis within past 6 month Bilirubin normal ( unless due Gilbert 's syndrome ) No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No prior proven gastric duodenal ulcer No clinically significant gastrointestinal blood loss within past 6 week Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior CNS hemorrhage No psychiatric illness social situation would preclude study compliance No concurrent uncontrolled illness No ongoing active infection No prior cilengitide ( EMD 121974 ) No concurrent biologic therapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No concurrent chemotherapy See Disease Characteristics More 4 week since prior radiotherapy recover No concurrent palliative radiotherapy No concurrent anticancer agent therapy intend treat malignancy No concurrent investigational agent No concurrent anticoagulation therapy increase INR aPTT normal range Line prophylaxis allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>